Topical IgA Secretory Component Mucositis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mucositis, particularly oral mucositis, are inadequate as they primarily focus on palliative measures and do not effectively address the underlying pathophysiological mechanisms, leading to significant discomfort, treatment delays, and increased healthcare costs.
Innovation Solution
Topical administration of immunoglobulin A (IgA) and/or IgM, specifically J chain-containing IgA or IgM, combined with secretory component, formulated as creams, gels, or liquids to provide prolonged contact with the mucosa, reduce microbial adherence, promote wound healing, and exert anti-inflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical immunoglobulin A is administered to treat mucositis, then wound healing is promoted and inflammation is reduced, but the complexity of the treatment composition increases
Solution Approach 1:
The patent employs a composite material strategy by combining immunoglobulin A with secretory component in a single topical formulation. This composite approach enhances treatment effectiveness for mucositis while managing the complexity through a defined two-component system that works synergistically to promote wound healing and reduce inflammation.
2Reliability
If J chain-containing IgA and secretory component are used together, then anti-inflammatory effects are enhanced, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies preliminary action by pre-combining immunoglobulin A with secretory component in a stabilized formulation before clinical use. This pre-prepared composite ensures the anti-inflammatory components are ready for immediate topical application to mucositis-affected areas, enhancing efficacy while simplifying the clinical administration process despite the complexity of manufacturing the stabilized composite.
3Reliability
If topical IgA composition is applied repeatedly to maintain prolonged contact, then treatment effectiveness is improved, but treatment time and cost increase
Solution Approach 1:
The patent implements continuity of useful action through the secretory component, which stabilizes the immunoglobulin A formulation and enables sustained release at the application site. This continuous action maintains therapeutic levels of IgA in contact with the mucosal tissue over extended periods, improving treatment effectiveness while reducing the frequency of reapplication needed compared to unstable formulations.
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis.